CoChat
Sign Up
Cited by 579Cannabis and Cannabinoid ResearchSubstance Abuse Treatment and OutcomesMental Health Treatment and Access

Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III

Open access
Hasin, Deborah S., Kerridge, Bradley T., Saha, Tulshi D., Huang, Boji, Pickering, Roger, Smith, Sharon M., Jung, Jeesun, Zhang, Haitao +1 more·2016·American Journal of Psychiatry
DOI 10.1176/appi.ajp.2015.15070907PMC PMC5026387
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Attitudes toward marijuana are changing, the prevalence of DSM-IV cannabis use disorder has increased, and DSM-5 modified the cannabis use disorder criteria. Therefore, updated information is needed on the prevalence, demographic characteristics, psychiatric comorbidity, disability, and treatment for DSM-5 cannabis use disorder. METHOD: In 2012-2013, 36,309 participants ≥18 years old were interviewed in the National Epidemiologic Survey on Alcohol and Related Conditions-III. Psychiatric and substance use disorders were assessed with the Alcohol Use Disorders and Associated Disabilities Interview Schedule-5. RESULTS: The prevalences of 12-month and lifetime cannabis use disorder were 2.5% and 6.3%. Among those with 12-month and lifetime diagnoses, the mean days of marijuana use per year were 225.3 (SE=5.7) and 274.2 (SE=3.8). The odds of 12-month and lifetime cannabis use disorder were higher for men, Native Americans, unmarried individuals, those with low incomes, and young adults (e.g., among those age 18-24 years versus ≥45: odds ratio for 12-month disorder, 7.2; 95% confidence interval, 5.5-9.5). Cannabis use disorder was associated with other substance use disorders, affective disorders, anxiety, and personality disorders. Twelve-month cannabis use disorder was associated with disability. As disorder severity increased, virtually all associations became stronger. Only 13.2% with lifetime cannabis use disorder participated in 12-step programs or professional treatment. CONCLUSIONS: DSM-5 cannabis use disorder is prevalent, associated with comorbidity and disability, and largely untreated. Findings suggest the need to improve prevention and educate the public, professionals, and policy makers about possible harms associated with cannabis use disorders and available interventions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.15070907

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The SF-12v2 is a reliable, valid, widely used measure of impairment in the prior 30 days.

    “Impaired functioning was assessed with version 2 of the 12-Item Short Form Health Survey (SF-12v2), a reliable, valid, widely used measure of impairment in the prior 30 days.39”

    From Epidemiology of Adult <i>DSM-5</i> Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [39]

    The Method > Disability/Impairment passage describes the SF-12v2 as a widely used measure of current disability and says the study used it to assess functioning. It does not specify a prior-30-day period or state that the SF-12v2 is reliable and valid; the reliability and validity statements in Method > Assessments concern a different interview. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Volkow ND Baler RD Compton WM Adverse health effects of marijuana use N Engl J Med 2014 370 2219 2227 24897085 PMC4827335
  2. [2]Hall W The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy 2009 20 458 466 19362460
  3. [4]Renard J Krebs MO Jay TM Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison Psychopharmacology (Berl) 2013 225 781 790 22983145
  4. [5]O’Shea M McGregor IS Mallet PE Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats J Psychopharmacol 2006 20 611 621 16714325
  5. [6]Lynskey M Hall W The effects of adolescent cannabis use on educational attainment: a review Addiction 2000 95 1621 1630 11219366
  6. [9]Lenne MG Dietze PM Triggs TJ The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand Accid Anal Prev 2010 42 859 866 20380913
  7. [10]Hartman RL Huestis MA Cannabis effects on driving skills Clin Chem 2013 59 478 492 23220273 PMC3836260
  8. [11]Brady JE Li G Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999–2010 Am J Epidemiol 2014 179 692 699 24477748 PMC3939850
  9. [12]Ramaekers JG Berghaus G van Laar M Dose related risk of motor vehicle crashes after cannabis use Drug Alcohol Depend 2004 73 109 119 14725950
  10. [13]Hartman RL Brown TL Milavetzd G Cannabis Effects on Driving Lateral Control With and Without Alcohol Drug Alcohol Depend 2015 In Press PMC4536116 26144593
  11. [15]Davis GP Compton MT Wang S Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions Schizophr Res 2013 151 197 202 24200416 PMC3877688
  12. [16]Di Forti M Marconi A Carra E Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study Lancet Psychiatry 2015 2 233 238 26359901
  13. [17]Stinson FS Ruan WJ Pickering R Cannabis use disorders in the USA: prevalence, correlates and co-morbidity Psychol Med 2006 36 1447 1460 16854249
  14. [18]Lev-Ran S Imtiaz S Taylor BJ Gender differences in health-related quality of life among cannabis users: results from the National Epidemiologic Survey on Alcohol and Related Conditions Drug Alcohol Depend 2012 123 190 200 22143039
  15. [19]Secades-Villa R Garcia-Rodriguez O Jin CJ Probability and predictors of the cannabis gateway effect: a national study Int J Drug Policy 2015 26 135 142 25168081 PMC4291295
  16. [21]Berg CJ Stratton E Schauer GL Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win Subst Use Misuse 2015 50 79 89 25268294 PMC4302728
  17. [22]Sinclair CF Foushee HR Scarinci I Perceptions of harm to health from cigarettes, blunts, and marijuana among young adult African American men J Health Care Poor Underserved 2013 24 1266 1275 23974397
  18. [24]Cerda M Wall M Keyes KM Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence Drug Alcohol Depend 2012 120 22 27 22099393 PMC3251168
  19. [25]Wall MM Poh E Cerda M Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear Ann Epidemiol 2011 21 714 716 21820632 PMC3358137
  20. [26]Hasin DS Wall M Keyes KM Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys Lancet Psychiatry 2015 2 601 608 26303557 PMC4630811
  21. [27]Bonn-Miller MO Harris AH Trafton JA Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009 Psychol Serv 2012 9 404 416 22564034
  22. [28]Compton WM Grant BF Colliver JD Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002 JAMA 2004 291 2114 2121 15126440
  23. [29]Hasin DS Saha TD Kerridge BT Marijuana use disorders in the United States between 2001–2002 and 2012–2013 In press JAMA Psychiatry 2015 PMC5037576 26502112
  24. [34]van der Pol P Liebregts N de Graaf R Mental health differences between frequent cannabis users with and without dependence and the general population Addiction 2013 108 1459 1469 23530710
  25. [36]Hasin DS O’Brien CP Auriacombe M DSM-5 criteria for substance use disorders: recommendations and rationale Am J Psychiatry 2013 170 834 851 23903334 PMC3767415
  26. [42]Grant BF Goldstein RB Chou SP The Alcohol Use Disorder and Associated Disabilities Interview Schedule Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Version (AUDADIS-5) Rockville, MD National Institute on Alcohol Abuse and Alcoholism 2011
  27. [43]Grant BF Harford TC Dawson DA The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample Drug Alcohol Depend 1995 39 37 44 7587973
  28. [44]Grant BF Goldstein RB Smith SM The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample Drug Alcohol Depend 2015 148 27 33 25595052 PMC5554948
  29. [45]Hasin DS Aivadyan C Greenstein E Psychiatric Research Interview for Substance Use and Mental Disorders, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PRISM-5) Version New York, NY Columbia University, Department of Psychiatry 2011
  30. [46]Hasin DS Greenstein E Aivadyan C The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample Drug Alcohol Depend 2015 148 40 46 25604321 PMC4330104
  31. [48]Gandek B Ware JE Jr Aaronson NK Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment J Clin Epidemiol 1998 51 1149 1158 9817132
  32. [50]Haberstick BC Young SE Zeiger JS Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health Drug Alcohol Depend 2014 136 158 161 24440049 PMC3963405
  33. [53]Eaton DK Kann L Kinchen S Youth risk behavior surveillance - United States, 2011 MMWR Surveill Summ 2012 61 1 162 22673000
  34. [58]Reboussin BA Green KM Milam AJ Neighborhood environment and urban African American marijuana use during high school J Urban Health 2014 91 1189 1201 25323775 PMC4242855
  35. [59]Ramanathan S Balasubramanian N Krishnadas R Macroeconomic environment during infancy as a possible risk factor for adolescent behavioral problems JAMA Psychiatry 2013 70 218 225 23277351
  36. [60]Melchior M Choquet M Le Strat Y Parental alcohol dependence, socioeconomic disadvantage and alcohol and cannabis dependence among young adults in the community Eur Psychiatry 2011 26 13 17 20627470
  37. [61]Tucker JS Pollard MS de la Haye K Neighborhood characteristics and the initiation of marijuana use and binge drinking Drug Alcohol Depend 2013 128 83 89 22938829 PMC3521064
  38. [64]Eaton NR Keyes KM Krueger RF An invariant dimensional liability model of gender differences in mental disorder prevalence: evidence from a national sample J Abnorm Psychol 2012 121 282 288 21842958 PMC3402021
  39. [65]Eaton NR Keyes KM Krueger RF Ethnicity and psychiatric comorbidity in a national sample: evidence for latent comorbidity factor invariance and connections with disorder prevalence Soc Psychiatry Psychiatr Epidemiol 2013 48 701 710 23052426 PMC3562755
  40. [66]Rubio JM Olfson M Villegas L Quality of life following remission of mental disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions J Clin Psychiatry 2013 74 e445 450 23759465
  41. [67]Keyes KM Hatzenbuehler ML McLaughlin KA Stigma and treatment for alcohol disorders in the United States Am J Epidemiol 2010 172 1364 1372 21044992 PMC2998202
  42. [68]Cohen E Feinn R Arias A Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions Drug Alcohol Depend 2007 86 214 221 16919401
  43. [69]van der Pol P Liebregts N de Graaf R Facilitators and barriers in treatment seeking for cannabis dependence Drug Alcohol Depend 2013 133 776 780 24035185
  44. [71]Danovitch I Gorelick DA State of the art treatments for cannabis dependence Psychiatr Clin North Am 2012 35 309 326 22640758 PMC3371269
  45. [72]Marshall K Gowing L Ali R Pharmacotherapies for cannabis dependence Cochrane Database Syst Rev 2014 12 CD008940 25515775 PMC4297244
  46. [73]Goldstein RB Chou SP Smith SM Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III J Stud Alcohol Drugs 2015 76 378 388 25978823 PMC4440296
  47. [74]Compton WM Dawson DA Goldstein RB Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol Drug Alcohol Depend 2013 132 387 390 23642316 PMC3748225
  48. [75]Hasin DS Keyes KM Alderson D Cannabis withdrawal in the United States: results from NESARC J Clin Psychiatry 2008 69 1354 1363 19012815 PMC2777674
  49. [76]Agrawal A Lynskey MT Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions Drug Alcohol Depend 2007 88 300 307 17084563 PMC1905146
  50. [78]Mitchell O Caudy MS Examining racial disparities in drug arrests Justice Quarterly 2015 32 288 313
  51. [80]Feingold D Fox J Rehm J Natural outcome of cannabis use disorder: a 3-year longitudinal follow-up Addiction 2015 7 25 [Epub ahead of print] 26212076

Cited by

Sorted by citations

Authors
Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung, J., Zhang, H., & Grant, B. F.
Affiliations
National Institute on Alcohol Abuse and Alcoholism (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2016-06-01
Volume
173
Issue
6
Pages
588-599
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.2015.15070907
PMC
PMC5026387
OpenAlex
W2289546590
Cited by
579
References
11
Citations by year
2026: 35 · 2025: 43 · 2024: 52 · 2023: 64 · 2022: 62 · 2021: 60 · 2020: 76 · 2019: 59 · 2018: 69 · 2017: 41 · 2016: 16
FWCI
49.91
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (R01DA034244, F32DA036431)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
cannabis use disorder, cannabis, DSM-5 diagnostic criteria, prevalence, psychiatric comorbidity, disability, substance use disorders, mood disorders, anxiety disorders, personality disorders, treatment utilization, demographic risk factors, young adults, Native Americans, low income
MeSH terms
Adolescent, Adult, Age Factors, Marijuana Abuse, Disability Evaluation, Female, Health Surveys, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Risk Factors, United States, Comorbidity, Prevalence, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review